

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Sherman Fong, et al.

Docket No.:

39780-1192-2C1

Serial No.:

10/791,618

Group Art Unit:

1647

Filing Date:

March 2, 2004

Examiner:

DeBerry, Regina M.

For:

NOVEL POLYPEPTIDES AND NUCLEIC ACIDS ENCODING

BOLEKINE

EXPRESS MAIL LABEL NO. EV 582 636 713 US

Date Mailed: OCTOBER 17, 2006

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

MAIL STOP — RCE

Commissioner for Patents PO Box 1450 Alexandria, Virginia 22313-1450

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy of each listed publication and U.S. and foreign patent, except for pending U.S. applications, is being submitted herewith, along with a concise explanation of information in a foreign language, if any, pursuant to 37 C.F.R. §1.97-1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If Form PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with M.P.E.P. §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

\boxtimes	This statement qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply):									
		(1) tha	an a c	•		oths of the application under § 1.53		te and is othe	er	
		(2	!)		l within 3 mor	oths of entry of a	national stage			
		(3) me	erits		l before the ma	ail date of the fir	st Office Actio	on on the		
	\boxtimes	(4) of	!)	It is being filed		ailing of a first C on under § 1.114		fter the filing	ŗ	
	37 C.F.R. $\S1.97(c)$. If this statement is being filed after the latest of: (1) three months beyond the filing date of a national application; (2) three months beyond the date of entry of the national stage as set forth in $\S1.491$ in an international application; or (3) the mailing date of a first Office action on the merits, but before the mailing date of the earlier of a final office action under $\S1.113$ or a notice of allowance under $\S1.311$, then:									
		a certificat	tion as	s specified in §1	1.97(e) is prov	ided below; or				
						thorized below, of th this statement		cluded with		
	37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, but before payment of the issue fee, then:									
	A.	a certification as specified in §1.97(e) is completed below; and								
·	B.	a petition under 37 C.F.R. §1.97(d) requesting consideration of this statement is submitted herewith; and								
	C.					authorized below th this statement		included wit	:h	
	Fee Authorization. The Commissioner is hereby authorized to charge the above-referenced fees of <u>\$0</u> and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. <u>08-1641 (Attorney's Docket No. 39780-1192-2C1).</u>									
					Respectfully	submitted,		- (Panas	Gas	
Dated:	October	r 17, 2006			By:Ginger	R. Dreger (Reg.	No. 33,055)	43	in Gao 16:6) hut of or Diegen	
		RMAN LL	P					المحادث كا	han en	
Menlo Telepho	one: (65	l Road difornia 94 50) 324-700 0) 324-0638	00	506				unge	rr wiejei	

		Form PTO-1	449 OTP !		Attorney's Docker 39780-1192-2C1	l No.		lication Seria 91,618	Il No.	
INFO	RMATIO	N DISCLOS	URE STATEMENT		Applicant(s)	BAK	(ER, et al.			
	(use sev	eral sheets i	if necessary)	- 1000 - 1000	Filing Date: May 14, 2002			up Art Unit: 7		
RADIENUS. PATENT DOCUMENTS										
Examiner Initials	Ref. No.	Date	Document No.	1	Name		Class	Subclass	Filing Date (if appropri	
	1.	10/1998	5,817,306		Haskill, et al.					
FOREIGN PATENT DOCUMENTS										
Examiner	Ref.	Date	Document No.		Name		Class	Subclass	Transla	tion
Initials	No.								YES	NO
									,	
OTHER DOGUMENTS (including author, title, date, pertinent pages, etc.)										
Examiner Initials	Ref. No.	Title								
	2.	Dziarski, Roman, "Enhancement of Mixed Leukocyte Reaction and Cytotoxic Antitumor Responses by Heparin," Journal of Immunology, Vol. 143, No. 1, pp. 356-365 (July 1989).								
	3.	McDyer, et al., "Patients with Multidrug-Resistant Tuberculosis with Low CD4+ T Cell Counts Have Impaired Th1 Responses," <i>The Journal of Immunology</i> , Vol. 158, pp. 492-500 (1997).								
	4.	McElrath, et al., "Cutaneous Response to Recombinant Interleukin 2 in Human Immunodeficiency Virus 1-Seropositive Individuals," <i>Proc. Natl. Acad. Sci, USA</i> , Vol. 87, pp. 5783-5787 (1990).								
	5.	Tyring, S., "Imiquimod Applied Topically: A Novel Response Modifier," Skin Therapy Letter, 6(6):1-4 (March 2001).								
	6.	Zaki, et al., "Synergistic Enhancement of Cell-Mediated Immunity by Interleukin-12 Plus Interleukin-2: Basis for therapy of Cutaneous T Cell Lumphoma," <i>J. Invest. Dermatol.</i> , Vol. 118, No. 2, pp. 366-371 (February 2002).								
						<u></u> .	<u> </u>			
						·				
			<u> </u>		<u>:</u>			_		
	-									
-							· _	- -	·	
		<u> </u>	<u> </u>						 	<u>.</u>
							-			
	,									

EXAMINER:	DATE CONSIDERED:						
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in							

EAAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).

SV 2239614 v1